This Medudy course is a video podcast for physicians on the PIFPAF-PFA study, which was presented as a late-breaking clinical trial at the 2026 ESC Congress in Munich and published simultaneously in JAMA. Prof. Dr. Christian-Hendrik Heeger and Prof. Dr. Roland Tilz discuss the first randomized study on additional posterior wall isolation (PWI) in combination with pulmonary vein isolation (PVI) using pulsed-field ablation (PFA) in patients with symptomatic persistent atrial fibrillation. They explain the design of the investigator-initiated, multicenter Swiss study involving 206 patients, who were randomized 1:1 to PVI alone versus PVI plus PWI using a Pentaspline PFA catheter; continuous rhythm monitoring with implantable event recorders; and the central primary endpoint —any atrial tachyarrhythmia lasting more than 30 seconds between days 91 and 365 (50.6% vs. 60.6%)—but a significantly lower atrial fibrillation burden and fewer prolonged episodes with additional posterior wall isolation. The experts explain why the posterior wall is a plausible ablation target, why PFA overcomes the safety and durability limitations of thermal energy forms, and why the 30-second rule and the small sample size may have masked the actual therapeutic effect. In addition, they discuss additional PFA applications and procedure time, concerns about hemolysis, and how they tailor posterior wall ablation in daily practice using 3D mapping and low-voltage zones.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance accessibility. The individuals on whom the avatars are based have expressly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by our medical team at Medudy.
By the end of this course, you will know:
- The design, patient population, and endpoints of the PIFPAF-PFA study comparing PVI alone with PVI plus posterior wall isolation using pulsed-field ablation in patients with persistent atrial fibrillation.
- the electrophysiological and embryological rationale for targeting the left atrial posterior wall for ablation, as well as the advantages of PFA over thermal energy sources in terms of esophageal safety and lesion durability.
- the results for the primary endpoint and the predefined secondary endpoints, in particular atrial fibrillation burden and recurrences lasting more than one hour.
- the study's limitations, including the strict 30-second definition of recurrence, the sample size, and the number of PFA applications delivered to the posterior wall.
- Why atrial fibrillation burden and quality of life might be more clinically relevant endpoints for ablation success than a single recurrence lasting more than 30 seconds.
- Practical strategies for the individualized use of posterior wall ablation in persistent atrial fibrillation, including 3D mapping, low-voltage areas, and moderate energy delivery.
